1Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancerUrology  Clinical Article
2Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trialThe Lancet Oncology  Clinical Article
3Defining a standard set of patient-centered outcomes for men with localized prostate cancerEuropean Urology  Full Text  Clinical Article
4Neo-adjuvant hormone therapy for non-metastatic prostate cancer: A systematic review and meta-analysis of 5,194 patientsWorld Journal of Surgical Oncology  Full Text  Review Article
5Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusEuropean Urology  Full Text  Clinical Article
63D vs 2D laparoscopic radical prostatectomy in organ-confined prostate cancer: Comparison of operative data and pentafecta rates: A single cohort studyBMC Urology  Full Text  Clinical Article
7Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score predictionMagnetic Resonance in Medicine  Clinical Article
8Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgeryEuropean Urology  Full Text  Clinical Article
9Sodium fluorescein use during intraoperative cystoscopyObstetrics and Gynecology  Clinical Article
10Economic evaluation of diagnostic localization following biochemical prostate cancer recurrenceInternational Journal of Technology Assessment in Health Care  Clinical Article
1Healthy-looking prostate cells mask cancer-causing mutationsCancer Research UK News
2Wake Forest Baptist first in state offering new prostate treatmentWake Forest Baptist Medical Center News
3Sophisticated application of magnetic force enhances laparoscopic surgeryVanderbilt University Medical Center Research News
4Rutgers Cancer Institute of New Jersey advances understanding of surgical treatment options for genitourinary cancersRutgers Cancer Institute of New Jersey News
5Black men less willing to be investigated for prostate cancerUniversity of Exeter Medical School
6Urine test could lead to better treatment of bladder cancerUniversity of Birmingham Medical News
7Mount Sinai researchers find chemotherapy after bladder cancer surgery improved survivalThe Mount Sinai Hospital
8UCLA study could point toward better decisions for treating men with prostate cancerUCLA Health System
9Lycopene may ward off kidney cancer in older womenWayne State University School of Medicine News
10Active surveillance of intermediate-risk prostate cancer associated with decreased survivalAmerican Society of Clinical Oncology (ASCO) News

Show Me:

GALNT4 predicts survival in patients with ccRCC

As reported in the Journal of Urology, N-acetylgalactosaminyltransferase 4 (GALNT4) levels are decreased in tumor specimens from patients with clear cell renal cell carcinoma (ccRCC; n=104) compared to peritumoral specimens. Decreased expression of GALNT4 is associated with poor OS (OR=3.08) and RFS (OR=2.17). Further, GALNT4 is negatively correlated with tumor size, necrosis, and TNM stage.

3-month PSA is a predictor of BCR-free survival after radical prostatectomy

As reported in the International Journal of Clinical Oncology, the 5-year biochemical recurrence (BCR)-free survival rate is significantly higher in patients with a 3-month PSA level < 0.010 ng/ml compared to patients with a 3-month PSA level between 0.010 and 100 ng/ml (92.6% vs. 57.4%). Amongst 174 men who underwent radical prostatectomy for clinically localized prostate cancer, 18.4% had a BCR and the median time to BCR was 16 months.

High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients

As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocSmoking only has a significant effect on the spontaneous passage of distal ureter stones when the diameter is >4 mm.

Clinical Pearl from Smartest DocThe odds ratio for premature ejaculation increases with the severity of LUTS or ED.

Clinical Pearl from Smartest DocSolifenacin has significantly lower efficacy in women with de novo overactive bladder after mid-urethral sling placement.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List